$QNRX News

Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003

Quoin Pharmaceuticals (NASDAQ:QNRX) Rises 12% on Q1 2026 Earnings Beat and Key Regulatory Milestones for QRX003

Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate

LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

Quoin Pharmaceuticals To Initiate Several Investigator-Led Clinical Studies For QRX009 Topical Rapamycin Lotion Application In Pachyonychia Congenita, Gorlin Syndrome, And Tuberous Sclerosis Complex; Company Expects To Submit IND Application To FDA In Q3

Quoin Pharmaceuticals To Initiate Several Investigator-Led Clinical Studies For QRX009 Topical Rapamycin Lotion Application In Pachyonychia Congenita, Gorlin Syndrome, And Tuberous Sclerosis Complex; Company Expects To Submit IND Application To FDA In Q3

QNRX: Preparing to Commercialize Lead Asset Through Global Sales Infrastructure

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Quoin Pharmaceuticals Q4 EPS $(1.74) Beats $(4.02) Estimate

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

Quoin Pharma Provides Clinical And Regulatory Update From Recent Constructive Type C Meeting With FDA For QRX003, For Treatment Of Netherton Syndrome

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Receives FDA's Fast Track Designation To QRX003 Lotion To Treat Netherton Syndrome

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

QNRX: Advancing Lead Asset QRX003, With Extensive Distribution Network in Place to Support Commercialization Prospects

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Submits Orphan Drug Designation Application To Japan's MHLW For QRX003 To Treat Netherton Syndrome

Quoin Pharmaceuticals Insider Ups Holding By 1,515,200% During Year

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome